Introduction
A C N U [ 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3-nitrosourea hydrochloride] is a water-and lipid-soluble nitrosourea derivative developed by A r a k a w a et at. in 1974 [1] . As an alkylating agent, it shows activity against transplanted human xenografts of GxF1 gastric cancer, MX1 breast cancer and CO4 colon cancer in nude mice [5] . P h a r m a c o l o g y studies in man reveal a plasma half-life of 35 rain following intravenous administration. The drug is excreted via the bile and urine.
In a phase I study performed in Japan [2] , dose-limiting toxicities consisted of granulocytopenia and thrombocytopenia; other toxicities observed included nausea, vomiting, and anorexia. Based on the results of this phase I study, a dose of 100 mg/m 2 to be given at intervals of 6 -8 weeks was recommended. The experience with A C N U in non-small-cell lung cancer is very limited. In a phase II study performed by Saijo and Niitani [3] , a response was observed in 5 of 28 patients (17.9%) with squamous-cell carcinoma of the lung. To confirm these results and to augment the current experience with A C N U in non-small-cell lung cancer, the E O R T C Lung Cancer Cooperative Group decided to perform a phase II study of A C N U in non-small-cell lung cancer.
Patients and methods
ACNU was given as a slow i. v. infusion at a dose of 100 mg/m 2 every 6 weeks. Due to haematological side effects observed in chemotherapypretreated patients, the dose was lowered during the study to 75 mg/m 2 every 6 weeks in this group. In cases of bone marrow suppression, retreatment was delayed until haematological recovery; a dose reduction of 25% was carried out in patients showing a WBC nadir of 1-2 • 109/t and/or a platelet nadir of 50-75 x 109/1. In subjects exhibiting a WBC nadir of <1 x 109/1 and/or a platelet nadir of <50 x 109/1, the dose was reduced to 50% of the previous level.
Patients in this study were required to have histologically proven non-small-cell lung cancer, locally advanced or metastastic, with measurable or evaluable lesions, documented progression within 2 months prior to entry into the study, an ECOG performance status of ~> 2, an age of <70 years, a WBC of >4x 109/1, a platelet count of >100• 109/1, a creatinine clearance of >40 ml/min and a serum bilirubin level of <2.5 mg/dl. All patients underwent a chest X-ray and, if indicated, a chest and/or abdominal computer-assisted tomographic (CT) scan before the start of treatment. During treatment, estimations of haemoglobin, WBC and platelets were done weekly and liver and renal functions were evaluated every 6 weeks. Response to treatment was assessed every 6 weeks according to WHO criteria [7] ; responses were reviewed extramurally.
Results
In this phase II study, pretreated and non-pretreated patients were analyzed separately. A total of 62 patients were entered; 34 subjects had not been pretreated and 28 had previously received various cisplatin-based chemotherapy regimens. 
The patients' characteristics are summarized in Table 1 . Overall, 50 subjects were fully evaluable for response and toxicity; 6 patients died before the first evaluation, scheduled at 6 weeks after the first ACNU dose: 3 due to rapidly progressive disease and 3 due to causes not related to tumor or treatment. Another 6 patients were not fully evaluable: therapy was stopped in 1 case because of severe thrombocytopenia at 4 weeks after the first dose (this patient was included in the toxicity analysis) and in 1 subject because of intercurrent gastro-intestinal disease; 1 patient received an inadequate dose and 3 refused further treatment after the first course.
Initially, 11 pretreated patients were started on an ACNU dose of 100 mg/m2; as 2 cases of grade 3 and 4 cases of grade 4 thrombocytopenia were observed, it was decided to lower the ACNU dose to 75 rag/m2 in this patient group. We observed a complete response in 1 patient with multiple lung metastases from an adenocarcinoma, which lasted for 9 months, and 2 partial responses: 1 in a local recurrence of an adenocarcinoma (for a duration of 9 months) and 1 in brain metastases from a squamous-cell carcinoma that lasted for 2 months. Two patients had not previously been treated; the response in the local recurrence occurred in a previously heavily protreated subject who was treated at a dose of 75 mg/m 2. The overall response rate was 5% (95% confidence limits, 1.7%-22.4%).
The observed toxicity consisted mainly of bone manow depression, including granulocytopenia of grades 3 (four cases) and 4 (one patient) and thrombocytopenia of grades 3 (seven subjects) and 4 (eight cases). Seven patients required platelet transfusions. One toxic death occurred due to an intracerebral haemorrhage during grade 4 thrombocytopenia. After lowering the ACNU dose in pretreated subjects we observed only 1 case of grade 3 and 1 of grade 4 thrombocytopenia in 14 patients. In the non-pretreated patients, four cases of grade 3 and three of grade 4 thrombocytopenia were observed, in one patient during the first course and in the others during the second and third courses. WBC nadirs occurred at week 4 and platelet nadirs, at week 5, causing treatment delays in five courses. Other toxicities observed were nausea and vomiting (grade 3 in 4 patients) and alopecia (grade 1 in 12 subjects).
Discussion
Prior to the cisplatin era, nitrosourea derivatives were frequently incorporated in chemotherapy regimens for non-small-cell lung cancer. CCNU and methyl-CCNU show some activity as single agents [6] but have the disadvantage of being lipid-soluble and must therefore be given by mouth. ACNU is lipid-and water-soluble and can be safely given intravenously. Apart from bone marrow toxicity, ACNU produces only minor gastrointestinal side effects; it lacks nephrotoxicity and pulmonary toxicity, in contrast to methyl-CCNU and BCNU. Because of these characteristics and the response rate of 17.8% previously observed in squamous-cell lung cancer [3] , our group considered it worthwhile to study ACNU in all histological subtypes of lung cancer. On the schedule used in the present study, we could not verify the results obtained by Saijo and Niitani [3] ; we observed 1 complete and 2 partial responses in 50 evaluable patients. Using a slightly lower dose, Sasaki et al. [4] observed no responders among 21 patients. The better results of Saijo and Niitani [3] cannot be explained by selection of histology. In our study, only 1 of 29 patients with squamous-cell carcinoma responded. The ACNU toxicity observed in this study consisted mainly of thrombocytopenia and tended to increase with continuation of treatment. We conclude that the activity of ACNU in non-small-cell lung cancer is negligible at this dose and on this schedule.
